Ranbaxy in-licenses NDDS cardiovascular drug

39820 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy in-licenses NDDS cardiovascular drug

Ranbaxy in-licenses NDDS cardiovascular drug from Ethypharm for Indian market.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy invalidates Pfizers 281 patent in the Netherlands Ranbaxy receives approval to mkt Loperamide Hydrochloride Ranbaxy wins 2 Lipitor patent cases in Norway Ranbaxy launches Soliten for treatment of urology disorder ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 28/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Earlier in May 2006, Ranbaxy had entered into a similar  in-licensing agreement with Ethypharm, India, for marketing of Tramadol Flashtab®, a pain management drug. It is Ranbaxy's strategic intent to in-licence other value added Drug Delivery products for the Indian market to supplement its significant portfolio in this area. Ranbaxy's strong marketing and distribution network coupled with its own expertise in the segment, makes it a partner of choice for companies evaluating similar collaborative go-to-market arrangements.

Ethypharm is a French company, present on the principal world health markets with manufacturing and R & D sites in Europe, North America, China and India. Ethypharm is headed by Gérard Leduc (Chairman and CEO) and Henry Martin (General Manager) since November 2005. The Ethypharm pharmaceutical company focuses on developing, manufacturing and licensing pharmaceutical products based on optimization of delivery through proprietary technologies, mainly in the oral sustained release formulations. The Company has a special focus on pain management, cardiovascular, oncology and CNS branded and generic products. Over the years, Ethypharm has developed more than 50 branded and generic products, based on its core proprietary technologies.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development.  The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries

Sourced From: Ranbaxy Laboratories Ltd.